Representative Chris Collins of New York may have violated federal law by sharing nonpublic information about a company on whose board he served, according to a report released Thursday by the Office of Congressional Ethics.

The report also said Mr. Collins may have broken House ethics rules by meeting with the National Institutes of Health and asking for help with the design of a clinical trial being set up by the company, Innate Immunotherapeutics. Mr. Collins, a Republican whose district encompasses much of western New York, is also the company’s largest shareholder, reporting for the year 2016 that he held between $25 million and $50 million in the company.

The House Committee on Ethics, which has the power to discipline members of the House for wrongdoing, said Thursday that it would further review the findings, a step short of opening a formal investigation. The bipartisan, quasi-independent office, which refers ethics issues to the committee, recommended the review by a unanimous vote.

Stanley Brand, a prominent criminal defense and ethics lawyer in Washington, said the ethics committee could still choose to drop the case. “It’s not a foregone conclusion that the ethics committee is going to take this up,” he said.